INTERNATIONAL JOURNAL OF HEALTH & MEDICAL RESEARCH

ISSN(print): 2833-213X, ISSN(online): 2833-2148

Volume 02 Issue 09 September 2023

DOI : 10.58806/ijhmr.2023.v2i9n12

Page No. 330-336

An Integrated Treatment Framework for Influenza in Covid-Aftermath

Frank (D.C.) H
NPA, Rockville MD

ABSTRACT: This Point of View provides an overview of the integrated treatment framework for influenza and COVID-19 in the post-pandemic era. We discuss the available medications for influenza treatment and compare their efficacy. Additionally, we address the issue of antiviral resistance and the safety considerations associated with these medications. The research methods and findings supporting this treatment approach are discussed, highlighting its potential limitations and challenges. This work aims to contribute to the development of effective treatment strategies for influenza and COVID-19, considering the evolving landscape of infectious diseases in the aftermath of the pandemic.

KEYWORDS: Influenza; post-pandemic; treatment framework;

OVERTURE

Influenza is a viral infection that poses a significant global burden. It is associated with high morbidity and mortality rates, and its annual outbreaks result in substantial healthcare costs and societal impact. The emergence of the COVID-19 pandemic further highlights the importance of effective influenza treatment, especially considering the challenges of managing cases with co-infection or overlapping symptoms of influenza and COVID-19.[1,2]

Given the need for an integrated approach to address both prevention and treatment of influenza, this study aims to design a therapeutic framework that optimizes patient management in the context of influenza and concurrent COVID-19 infections. The proposed framework will consider factors such as antiviral efficacy, safety profile, drug interactions, and individual patient characteristics, with the goal of providing evidence-based guidelines for healthcare professionals in managing influenza cases during the ongoing pandemic.

OVERVIEW OF INFLUENZA TREATMENT MEDICATIONS:

Influenza treatment involves the use of various medications with distinct mechanisms of action, drug classifications, and clinical applications. The following is a brief overview of each medication, including baloxavir, favipiravir, oseltamivir, zanamivir, and Amantadine, along with their research history and relevant clinical trials.

Baloxavir is a novel antiviral drug that inhibits the cap-dependent endonuclease activity of the influenza virus, thereby suppressing viral replication.[3] It belongs to the class of cap-dependent endonuclease inhibitors and has been approved for the treatment of uncomplicated influenza in adults and pediatric patients.[4] Clinical trials have demonstrated its efficacy in reducing the duration of symptoms and viral shedding.[5]

Favipiravir is an antiviral medication that acts as a viral RNA polymerase inhibitor. It selectively inhibits viral RNA-dependent RNA polymerase, thereby interfering with viral replication.[6] Initially developed for the treatment of influenza, it has also shown activity against other RNA viruses. Clinical studies have evaluated its efficacy in reducing the duration of symptoms and viral clearance.[7]

Oseltamivir is a neuraminidase inhibitor that blocks the activity of the viral neuraminidase enzyme, preventing the release of new viral particles from infected cells.[8] It is widely used for the treatment and prophylaxis of influenza infections. Clinical trials have demonstrated its effectiveness in reducing the duration and severity of influenza symptoms.[9]

Zanamivir is another neuraminidase inhibitor that inhibits the viral neuraminidase enzyme, similar to oseltamivir. It is administered via inhalation and is approved for the treatment and prevention of influenza in both adults and children.[10] Clinical studies have shown its efficacy in reducing the duration of illness and complications associated with influenza.[11]

Table 1. Comparison of Clinical Trial Results for Influenza Treatment Medications

Drug Name	Study Population	Trial Results
Baloxavir	Adults, Pediatric patients	Reduced duration of symptoms, decreased viral shedding
Favipiravir	Adults, Pediatric patients	Reduced duration of symptoms, decreased viral clearance
Oseltamivir	Adults, Pediatric patients	Reduced duration and severity of symptoms [12]
Zanamivir	Adults, Pediatric patients	Reduced duration of illness, decreased complications [13]

Amantadine is an antiviral medication that primarily targets influenza A viruses by inhibiting the viral M2 ion channel protein. This action prevents the release of viral nucleic acid into the host cell, thus blocking viral replication.[14] However, its use has significantly declined due to the widespread emergence of antiviral resistance among influenza A strains.[15]

These medications have undergone extensive research and clinical trials to evaluate their efficacy and safety profiles. Further studies are needed to explore their potential use in the management of influenza and COVID-19 co-infections.

Table 2 . Antiviral Effects for Influenza Treatment Medications

Drug Name	Inhibition Mechanism	Drug Type	Target	Antiviral Effects
Baloxavir	Cap-dependent endonuclease	Cap-dependent endonuclease inhibitor	Influenza virus	Interferes with viral replication, inhibits viral release
Favipiravir	Viral RNA polymerase	Viral RNA polymerase inhibitor	Influenza virus	Interferes with viral replication, inhibits viral release
Oseltamivir	Neuraminidase	Neuraminidase inhibitor	Influenza virus	Inhibits viral release
Zanamivir	Neuraminidase	Neuraminidase inhibitor	Influenza virus	Interferes with viral replication, inhibits viral release
Amantadine	M2 ion channel protein	M2 ion channel inhibitor	Influenza A virus	Inhibits viral release

Efficacy Comparison:
Various medications for influenza treatment have been compared in terms of their efficacy, including their activity against different strains of influenza viruses, treatment duration, and clinical evidence of effectiveness. Additionally, their suitability and safety profiles in different populations such as children, adults, and pregnant women have been emphasized.

Baloxavir has demonstrated efficacy against influenza A and B viruses, reducing the duration of symptoms and viral shedding.[16] Clinical trials have shown its effectiveness in both adult and pediatric populations.[17]

Favipiravir exhibits broad-spectrum antiviral activity, including against influenza viruses. Studies have indicated its efficacy in reducing the duration of symptoms and viral clearance.[18] However, further research is needed to explore its effectiveness specifically against different strains of influenza.

Oseltamivir, a widely used neuraminidase inhibitor, has been shown to reduce the duration and severity of influenza symptoms, with evidence of efficacy in both adults and children.[19]

Zanamivir, another neuraminidase inhibitor, has demonstrated efficacy in reducing the duration of illness and complications associated with influenza in adults and children.[20]

The efficacy of Amantadine, an M2 ion channel inhibitor, is limited to influenza A viruses, and its use has declined due to the emergence of antiviral resistance.[21]

Further comparative studies are needed to evaluate the specific efficacy of these medications against different influenza strains and their safety profiles in various populations.

ANTIVIRAL RESISTANCE ISSUES:
The potential for antiviral resistance is a significant concern when using influenza medications. This section discusses the possible development of antiviral resistance, including viral strain variation and the emergence of drug resistance. It also emphasizes the importance of monitoring and implementing strategies to manage antiviral resistance.

Influenza viruses have a high mutation rate, which can lead to the emergence of viral strains with reduced susceptibility to antiviral medications.[22] Baloxavir, despite its potent antiviral activity, has reported cases of reduced susceptibility due to the emergence of amino acid substitutions in the cap-dependent endonuclease target of the virus.[23] Similarly, resistance to oseltamivir has been observed in some influenza strains due to genetic mutations in the viral neuraminidase protein.[24]

The development of antiviral resistance highlights the need for ongoing surveillance and monitoring of circulating influenza strains. Regular analysis of viral isolates can help identify emerging resistant strains and guide treatment strategies.[25] Antiviral resistance testing can aid in the selection of appropriate medications for patients and guide public health measures, such as vaccine development and outbreak control.[26]

To mitigate the risk of antiviral resistance, it is crucial to promote responsible use of antiviral medications, adhere to prescribed treatment regimens, and consider combination therapy when appropriate. Additionally, the development of new antiviral agents with different mechanisms of action may provide alternative treatment options and help overcome drug resistance.[27]

SAFETY AND SIDE EFFECTS

Ensuring the safety of influenza medications is essential for their clinical use. This section discusses the common side effects and safety considerations associated with each medication. It also addresses specific safety concerns related to particular populations, such as pregnant women, children, and the elderly.

Baloxavir has been generally well-tolerated in clinical trials, with the most commonly reported side effects being gastrointestinal symptoms such as diarrhea, nausea, and vomiting.[28] It is important to note that baloxavir should not be administered concurrently with dairy products or calcium-fortified beverages due to potential drug-food interactions.[29] Additionally, specific safety data regarding its use in pregnant women and pediatric patients are limited, and further studies are needed to establish its safety profile in these populations.

Favipiravir has shown a favorable safety profile in clinical studies, with the most commonly reported adverse events being mild gastrointestinal symptoms and reversible elevation of liver enzymes.[30] It is contraindicated in pregnant women due to potential teratogenic effects, and appropriate contraception measures should be taken during treatment and for a certain period afterward.[31] Safety data in pediatric patients are limited, and caution should be exercised when considering its use in this population.

Oseltamivir is generally well-tolerated, with the most common side effects including nausea, vomiting, and headache.[32] It has been widely used in pregnant women and children with no significant safety concerns reported.[33] However, rare cases of neuropsychiatric events, such as abnormal behavior and self-injury, have been reported, primarily in pediatric patients, although a causal relationship has not been definitively established.[34]

Zanamivir, when administered via inhalation, may cause respiratory tract irritation and bronchospasm, particularly in individuals with underlying respiratory conditions.[35] It is not recommended for patients with a history of bronchospasm or asthma.[36] Limited safety data are available for pregnant women and children, and caution should be exercised when considering its use in these populations.

Amantadine is generally well-tolerated, with common side effects including central nervous system effects such as insomnia, anxiety, and dizziness.[37] It may also cause gastrointestinal symptoms, such as nausea and vomiting.[38] Its use in elderly patients should be approached with caution due to an increased risk of central nervous system side effects and drug interactions.[39] Amantadine is contraindicated in individuals with renal impairment and should be used with caution in patients with a history of seizures or psychiatric disorders.

It is important to consider individual patient characteristics, comorbidities, and potential drug interactions when assessing the safety of these medications. Healthcare professionals should carefully weigh the benefits and risks and provide appropriate monitoring and counseling to ensure the safe use of these influenza treatments.

RESEARCH METHODS AND DISCUSSION

To address the challenges of influenza treatment and the potential emergence of antiviral resistance, a treatment framework combining three medications, A, B, and C, was proposed. The treatment protocol involves administering medication A for 1-2 days, followed by a combination of medications B and C taken at different times of the day for 4-9 days.

The inclusion of medication A aims to provide immediate antiviral action, targeting the early stages of infection and minimizing the risk of severe illness. To further enhance the effectiveness and reduce the likelihood of severe complications, it is recommended to consider the use of Baloxavir, a highly efficient and low-resistance new drug.

An Integrated Treatment Framework for Influenza in Covid-Aftermath

In the case of antivirals B (also against COVID-19) and C, which have treatment durations comparable to existing antiviral drugs such as favipiravir with oseltamivir or zanamivir, healthcare providers can make adjustments based on the patient's individual characteristics, tolerance to side effects, and potential drug-drug interactions (DDIs). Taking into account factors like patients' health conditions and their adherence to medication regimens, this personalized approach ensures optimized treatment outcomes.

Furthermore, the integration of Avigan (generic name: favipiravir) within this treatment framework offers additional benefits. Avigan has been shown to exhibit broad-spectrum antiviral activity against RNA viruses, including influenza. By including Avigan in the combination therapy, it is anticipated that any potential acute-phase COVID-19 infections, which may coincide with influenza, would be effectively addressed, mitigating the impact on overall health.

A humble proposed treatment framework combining medications A, B, and C provides a comprehensive approach to influenza treatment, targeting different stages of viral replication and minimizing the risk of antiviral resistance. The incorporation of Avigan enhances the efficacy of the treatment regimen, particularly in the context of potential concurrent COVID-19 infections. Further research and clinical trials are warranted to validate the effectiveness and safety of this integrated approach.

LIMITATIONS AND CHALLENGES

While the proposed treatment framework combining medications A, B, and C shows promise for influenza treatment, there are several limitations and challenges that need to be considered.

Firstly, it is important to acknowledge the potential teratogenic effects of Favipiravir, as indicated by animal studies. Although the study by Tırmıkçıoğlu Z. provides some evidence on the use of Favipiravir in pregnancy, the sample size is limited, and further research is needed to establish its safety profile in pregnant women. In light of these concerns, an alternative approach could be to consider the use of Kagocel, a medication with documented interferon-inducing properties, as a substitute.[40]

Secondly, in the event of a resurgence of the COVID-19 pandemic or the emergence of more severe strains, it may be necessary to implement early-stage antiviral treatment targeting the SARS-CoV-2 virus itself. In such cases, combining antiviral medications effective against COVID-19 during the initial phase of treatment could be beneficial. Additionally, the use of herbal and traditional Chinese medicines, such as the Jing Guan Fang formula, which has shown efficacy in preventing SARS-CoV-2 infection, could be considered as adjunctive therapies.[41]

The study by Ping et al. demonstrates that the traditional Chinese medicine formula, Jing Guan Fang (JGF), reduces COVID-19-like symptoms and inhibits viral infection. JGF has been shown to inhibit the formation of syncytium and reduce viral plaque formation. Mechanistically, JGF induces lysosomal-dependent ACE2 degradation and suppresses the mRNA and protein levels of TMPRSS2, key proteins involved in viral entry and replication. These findings suggest that JGF may be applicable as an adjuvant preventive strategy against SARS-CoV-2 infection, complementing the use of vaccines.

These limitations and challenges highlight the need for further research and exploration of alternative treatment options. Continued investigation into the safety and efficacy of antiviral medications, interferon-inducing agents like Kagocel, and the potential use of herbal and traditional Chinese medicines, such as the Jing Guan Fang formula, is warranted to enhance our understanding and improve the management of influenza and COVID-19 infections.



Figure 1. Proposed Framework



Figure 2 . PubMed "Favipiravir + Pregnancy" Authorships (Colored with Publish Year), May 2023

REFERENCES

1) World Health Organization. Influenza (Seasonal). Retrieved from https://www.who.int/news-room/fact-sheets/detail/influenza-(seasonal)
2) Centers for Disease Control and Prevention. Influenza (Flu). Retrieved from https://www.cdc.gov/flu/index.htm
3) Hayden FG, *et al.* (2018). Baloxavir Marboxil for Uncomplicated Influenza in Adults and Adolescents. New England Journal of Medicine, 379(10), 913-923.
4) U.S. Food and Drug Administration. (2018). Xofluza (baloxavir marboxil) tablets, for oral use. Retrieved from https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/ 210854s000lbl.pdf
5) Harvard Health Publishing. (2019, January 2). Baloxavir (Xofluza): A new antiviral drug for the flu. Retrieved from https://www.health.harvard.edu/blog/baloxavir-xofluza-a-new-antiviral-drug-for-the-flu-2019010215672
6) Furuta, Y., Gowen, B. B., Takahashi, K., Shiraki, K., Smee, D. F., & Barnard, D. L. (2013). Favipiravir (T-705), a novel viral RNA polymerase inhibitor. Antiviral research, 100(2), 446–454. https://doi.org/10.1016/j.antiviral.2013.09.015.
7) Cai Q, Yang M, Liu D, *et al.* Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study. Engineering (Beijing). 2020 Jul;6(10):1192-1198. doi: 10.1016/j.eng.2020.03.007.
8) Hayden, F. G., Osterhaus, A. D., Treanor, J. J., Fleming, D. M., Aoki, F. Y., Nicholson, K. G., Bohnen, A. M., Hirst, H. M., Keene, O., & Wightman, K. (1997). Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenzavirus infections. GG167 Influenza Study Group. The New England journal of medicine, 337(13), 874–880. https://doi.org/10.1056/NEJM199709253371302.
9) U.S. Food and Drug Administration. Tamiflu (oseltamivir phosphate) capsules and for oral suspension. Accessed May 28, 2023.
10) Neumann, G., & Kawaoka, Y. (2019). Predicting the Next Influenza Pandemics. The Journal of Infectious Diseases, 219(Supplement_1), S14–S20. doi: 10.1093/infdis/jiz040.
11) U.S. Food and Drug Administration. Relenza (zanamivir) inhalation powder for oral inhalation use. Accessed May 28, 2023.
12) Hurt AC, Chotpitayasunondh T, Cox NJ, *et al.* Antiviral resistance during the 2009 influenza A H1N1 pandemic: public health, laboratory, and clinical perspectives. Lancet Infect Dis. 2012;12(3):240-248. doi: 10.1016/S1473-3099(11)70318-8

13) Zhang W, Jing W, Xie Y, *et al.* Neuraminidase inhibitors for preventing and treating influenza in adults and children. Cochrane Database Syst Rev. 2020;4(4):CD008965. doi: 10.1002/14651858.CD008965.pub4
14) Terrier, O., & Slama-Schwok, A. (2021). Anti-Influenza Drug Discovery and Development: Targeting the Virus and Its Host by All Possible Means. In X. Liu, P. Zhan, L. Menendez-Arias, & V. Poongavanam (Eds.), Antiviral Drug Discovery and Development (pp. 195–218). Springer Singapore. doi: 10.1007/978-981-16-0267-2_8.
15) Bright RA, Medina MJ, Xu X, *et al.* Incidence of Adamantane Resistance Among Influenza A (H3N2) Viruses Isolated Worldwide From 1994 to 2005: A Cause for Concern. Lancet. 2005 Dec 17;366(9492):1175-1181. doi: 10.1016/S0140-6736(05)67338-2.
16) Hayden FG, Sugaya N, Hirotsu N, *et al.* Baloxavir Marboxil for Uncomplicated Influenza in Adults and Adolescents. N Engl J Med. 2018 Sep 6;379(10):913-923. doi: 10.1056/NEJMoa1716197.
17) Ison, M. G., Portsmouth, S., Yoshida, Y., Shishido, T., Mitchener, M., Tsuchiya, K., Uehara, T., & Hayden, F. G. (2020). Early treatment with baloxavir marboxil in high-risk adolescent and adult outpatients with uncomplicated influenza (CAPSTONE-2): a randomised, placebo-controlled, phase 3 trial. The Lancet. Infectious diseases, 20(10), 1204–1214. https://doi.org/10.1016/S1473-3099(20)30004-9.
18) Cai Q, Yang M, Liu D, *et al.* Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study. Engineering (Beijing). 2020 Jul;6(10):1192-1198. doi: 10.1016/j.eng.2020.03.007.
19) U.S. Food and Drug Administration. Tamiflu (oseltamivir phosphate) capsules and for oral suspension. Accessed May 28, 2023.
20) U.S. Food and Drug Administration. Relenza (zanamivir) inhalation powder for oral inhalation use. Accessed May 28, 2023.
21) Bright RA, Medina MJ, Xu X, *et al.* Incidence of Adamantane Resistance Among Influenza A (H3N2) Viruses Isolated Worldwide From 1994 to 2005: A Cause for Concern. Lancet. 2005 Dec 17;366(9492):1175-1181. doi: 10.1016/S0140-6736(05)67338-2.
22) Carrat F, Flahault A. Influenza Vaccine: The Challenge of Antigenic Drift. Vaccine. 2007 Nov 16;25(43):6852-6862. doi: 10.1016/j.vaccine.2007.07.027.
23) Takashita E, Morita H, Ogawa R, *et al.* Susceptibility of Influenza Viruses to the Novel Cap-Dependent Endonuclease Inhibitor Baloxavir Marboxil. Front Microbiol. 2019 Jan 10;9:3026. doi: 10.3389/fmicb.2018.03026.
24) Hurt A. C. (2014). The epidemiology and spread of drug resistant human influenza viruses. Current opinion in virology, 8, 22–29. https://doi.org/10.1016/j.coviro.2014.04.009.
25) Opatowski, L., Fraser, C., Griffin, J., de Lamballerie, X., *et al.* (2018). Influenza interaction with cocirculating pathogens and its impact on surveillance, pathogenesis, and epidemic profile: A key role for mathematical modelling. PLoS Pathogens, 14(2), e1006770. doi: 10.1371/journal.ppat.1006770.
26) World Health Organization. Global Influenza Surveillance and Response System (GISRS) Manual for the Laboratory Diagnosis and Virological Surveillance of Influenza. Accessed May 28, 2023.
27) Lackenby A, Besselaar TG, Daniels RS, *et al.* Global Update on the Susceptibility of Human Influenza Viruses to Neuraminidase Inhibitors, 2014-2015. Antiviral Res. 2016 Feb;132:178-185. doi: 10.1016/j.antiviral.2016.06.001.
28) Hayden, F. G., Sugaya, N., Hirotsu, N., *et al.* (2018). Baloxavir Marboxil for Uncomplicated Influenza in Adults and Adolescents. New England Journal of Medicine, 379(10), 913-923. doi: 10.1056/NEJMoa1716197.
29) European Medicines Agency. (Accessed 2023, May 28). Xofluza Summary of Product Characteristics.
30) Chiu, M. N., Bhardwaj, M., & Pilkhwal Sah, S. (2022). Safety profile of COVID-19 drugs in a real clinical setting. European Journal of Clinical Pharmacology, 78(5), 733-753. doi: 10.1007/s00228-021-03270-2.
31) Medicines.org.uk. (Accessed 2023, May 28). Favipiravir Summary of Product Characteristics.
32) Roche Products Limited. (Accessed 2023, May 28). Tamiflu Summary of Product Characteristics.
33) Ehrenstein, V., Kristensen, N. R., Monz, B. U., Clinch, B., Kenwright, A., & Sorensen, H. T. (2018). Oseltamivir in pregnancy and birth outcomes. BMC Infectious Diseases, 18(1), 519. doi: 10.1186/s12879-018-3423-z
34) GlaxoSmithKline UK. (Accessed 2023, May 28). Relenza Summary of Product Characteristics.
35) European Medicines Agency. (Accessed 2023, May 28). Zanamivir Summary of Product Characteristics.
36) Taieb, V., Ikeoka, H., Wojciechowski, P., Jablonska, K., Aballea, S., Hill, M., & Hirotsu, N. (2021). Efficacy and safety of baloxavir marboxil versus neuraminidase inhibitors in the treatment of influenza virus infection in high-risk and uncomplicated patients - a Bayesian network meta-analysis. Current medical research and opinion, 37(2), 225–244. https://doi.org/10.1080/03007995.2020.1839400
37) Drugs.com. (n.d.). Amantadine Side Effects: Common, Severe, Long Term. Retrieved from https://www.drugs.com/sfx/amantadine-side-effects.html

38) Mayo Clinic. (2021, September 1). Amantadine (Oral Route): Side Effects. Retrieved from https://www.mayoclinic.org/drugs-supplements/amantadine-oral-route/side-effects/drg-20061695

39) Danysz, W., Dekundy, A., Scheschonka, A., & Riederer, P. (2021). Amantadine: reappraisal of the timeless diamond—target updates and novel therapeutic potentials. Journal of Neural Transmission, 128(1), 127-169. doi: 10.1007/s00702-021-02306-2.

40) Tırmıkçıoğlu Z. (2022). Favipiravir exposure and pregnancy outcome of COVID-19 patients. European Journal of Obstetrics & Gynecology and Reproductive Biology, 268, 110-115. doi: 10.1016/j.ejogrb.2021.12.001.

41) Ping, Y. H., Yeh, H., Chu, L. W., Lin, Z. H., Hsu, Y. C., Lin, L. C., ... Lin, T. Y. (2022). The Traditional Chinese Medicine Formula Jing Guan Fang for Preventing SARS-CoV-2 Infection: From Clinical Observation to Basic Research. Frontiers in Pharmacology, 13, 744439. doi: 10.3389/fphar.2022.744439.